Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Effect of apolipoprotein E (APOE) on Alzheimer's disease and related dementias (ADRD) risk is heterogeneous across populations, with scarce data on Hispanics/Latinos. Methods APOE genotype was studied in 12,221 Hispanics/Latinos (per cohort and via metanalysis): Caribbean-Hispanics, Mexicans, Mexican-Americans, and Peruvians/Bolivians. A subsample had longitudinal assessment and plasma p-tau. We tested the modifying effects of global and local ancestries. Results were replicated in an independent Peruvian cohort and brain samples. Results APOE ε4 effect was strongest in Peruvians/Bolivians (odds ratio [OR] = 6.13, 95% confidence interval [CI] = 2.71-13.83), followed by Mexicans (OR = 4.31, 95% CI = 1.58-11.74), Mexican-Americans (OR = 3.06, 95% CI = 2.04-4.59), and Caribbean-Hispanics (OR = 2.22, 95% CI = 1.99-2.48). Meta-analyses showed OR = 2.32 (95% CI = 2.09-2.57) and OR = 0.81 (95% CI = 0.68-0.97) for the ε4 and ε2 allele, respectively. The APOE ε4 effect was replicated independently in Peruvians (OR = 5.06, 95% CI = 2.48-10.70). ε4 carriers displayed higher ADRD conversions and p-tau levels. Global and local ancestries did not modify ADRD risk, and they were associated with Braak stage. Discussion APOE shows a heterogeneous effect on ADRD risk in our Hispanics/Latinos sample, the largest to date. Highlights The apolipoprotein E (APOE) ε4 effect is stronger in Peruvians/Bolivians than in other Hispanic/Latino groups. The strong APOE effect size in Peruvians and Bolivians was replicated in a second independent Peruvian cohort. Meta-analysis for ε4 and ε2 confirmed a significant association with Alzheimer's disease and related dementias (ADRD). Global and local ancestry do not modify the association between APOE genotype and ADRD.

What this study adds

Evidence grade: Moderate

This is a case-control study of 12,221 participants. Among 12,221 Hispanics/Latinos, the APOE ε4 effect on Alzheimer's disease and related dementias risk varied across groups, strongest in Peruvians/Bolivians and weakest in Caribbean-Hispanics. Reported effect size: APOE ε4 meta-analytic OR 2.32 (95% CI 2.09-2.57); range 2.22 (Caribbean-Hispanics) to 6.13 (Peruvians/Bolivians).

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Barral, S., Yang, Z., Phillips, N., Barber, R. C., Brickman, A. M., Honig, L. S., et al. (2025). APOE and Alzheimer's disease and related dementias risk among 12,221 Hispanics/Latinos. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70138

Vancouver

Barral S, Yang Z, Phillips N, Barber RC, Brickman AM, Honig LS, et al. APOE and Alzheimer's disease and related dementias risk among 12,221 Hispanics/Latinos. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70138. PMID: 40219824.

BibTeX

@article{barral2025-40219824,
  author  = {Barral, S. and Yang, Z. and Phillips, N. and Barber, R. C. and Brickman, A. M. and Honig, L. S. and Cieza, B. and Reyes-Dumeyer, D. and Mayeux, R. and Rajabli, F. and others},
  title   = {{APOE and Alzheimer's disease and related dementias risk among 12,221 Hispanics/Latinos}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70138},
  pmid    = {40219824},
  url     = {https://doi.org/10.1002/alz.70138}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Among 12,221 Hispanics/Latinos, the APOE ε4 effect on Alzheimer's disease and related dementias risk varied across groups, strongest in Peruvians/Bolivians and weakest in Caribbean-Hispanics. The ε4 effect was replicated in an independent Peruvian cohort, and ε4 carriers had higher dementia conversions and p-tau levels.

Study details

Limitations

Case-control design with differing recruitment across cohorts; wide confidence intervals in the smaller groups; dementia diagnoses not uniformly biomarker-confirmed.

How this study scored 64/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 6 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 63 of the 98 points it could be judged on, which is 64 of 100. Total 64 of 100.63 of the 98 points we could judge = 64 of 100

Published in a leading specialty journal, and it is a case-control study. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 63 of the 98 points we could judge it on, which is 64 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 6 / 12 A case-control study
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 12,221 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 12 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.0 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 6.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 3 other studies in this library
Still being cited 1 / 4 Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Giuseppe Tosto: h-index 32 (OpenAlex, whole career)
Institution's track record 2 / 3 Columbia University: institution h-index 1,824 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 17 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40219824)
Free to read — / 2 Access not recorded — left out of this score
Points 63 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 63 of the 98 points we could judge it on is 64 out of 100.
Total 64 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Genetics from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Genetics

See all studies in Genetics →